Topigen Pharmaceuticals reports successful Phase II trial for NicOx drug

Results for the trial, which evaluated TPI-1020, showed a good safety and tolerability profile, in addition to certain anti-inflammatory effects, which could be beneficial in Topigen’s target indication of chronic obstructive pulmonary disease (COPD). Canada-based Topigen plans to initiate a Phase II study in patients with COPD during the second half of 2007.

The trial was initiated in May 2006 and was a 21-day, multi-center, double blind trial in asthmatic smokers who were randomized to receive repeated and ascending doses of either inhaled TPI-1020 or budesonide, a conventional corticosteroid used in respiratory disorders.